Eötvös Loránd University, Hungarian Academy of Sciences, Research Group of Peptide Chemistry, Budapest, Pázmány P. stny. 1/A, Hungary.
Expert Opin Ther Pat. 2009 Dec;19(12):1771-85. doi: 10.1517/13543770903410237.
Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications.
OBJECTIVE/METHOD: Here we give an overview of the most relevant LH-RH antagonists and their therapeutic applications. Recently patented compounds as well as drug formulations and dosage are presented.
LH-RH antagonists have found clinical applications in in vitro fertilization, benign prostatic hyperplasia, endometriosis and in the treatment of hormone-dependent tumors. Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists.
促黄体生成素释放激素(LH-RH)通过调节性腺活动在脊椎动物生殖中发挥核心作用。基于其与垂体 LH-RH 受体的结合,以及与癌细胞上表达的 LH-RH 受体的结合,LH-RH 激动剂和拮抗剂已被开发用于不同的治疗应用。
目的/方法:本文概述了最相关的 LH-RH 拮抗剂及其治疗应用。介绍了最近获得专利的化合物以及药物制剂和剂量。
LH-RH 拮抗剂已在体外受精、良性前列腺增生、子宫内膜异位症和激素依赖性肿瘤的治疗中得到临床应用。目前的工作重点是进一步开发肽类和口服活性非肽类 LH-RH 拮抗剂。